Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)

EXCLI Journal

Volumn 13, Issue , 2014, Pages 869-896

  Wanwimolruk, Sompon ^a   Phopin, Kamonrat ^a   Prachayasittikul, Virapong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Chinese herbal medicines; CYP; Dietary supplements; Drug interactions; Herbal drug interactions; Herbal medicines

Indexed keywords

ALPRAZOLAM; BUSPIRONE; CAFFEINE; CHLORZOXAZONE; CIMICIFUGA RACEMOSA EXTRACT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEBRISOQUINE; DEXTROMETHORPHAN; GINSENG EXTRACT; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; INDINAVIR; KAVA EXTRACT; LOSARTAN; MIDAZOLAM; RESVERATROL; SALVIA MILTIORRHIZA EXTRACT; WARFARIN;

ACTAEA RACEMOSA; ANGELICA SINENSIS; CHINESE HERB; CHINESE MEDICINE; CODONOPSIS; CODONOPSIS TANGSHEN; DRUG INHIBITION; DRUG POTENTIATION; DRUG QUALITY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GINSENG; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; NONHUMAN; OLDENLANDIA; OLDENLANDIA DIFFUSA; PATIENT EDUCATION; PHARMACODYNAMICS; PIPER METHYSTICUM; REHMANNIA GLUTINOSA; REVIEW; SABAL; SALVIA MILTIORRHIZA; TEA;

EID: 84907702363     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. An G, Morris ME. Herbal supplement-based interactions. In: Pang KS, Rodrigues AD, Peter RM (eds): Enzyme-and transporter-based drug-drug interactions (pp 555-84). New York: Springer, 2010.
2. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003;43:643-8.
3. Andrade AS, Hendrix C, Parsons TL, Caballero B, Yuan CS, Flexner CW et al. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med 2008;8:50.
4. Astill C, Birch MR, Dacombe C, Humphrey PG, Martin PT. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. J Agric Food Chem 2001;49:5340-7.
5. Bagchi D, Garg A, Krohn RL, Bagchi M, Bagchi DJ, Balmoori J et al. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen Pharmacol 1998;30:771-6.
6. Bagchi D, Bagchi M, Stohs S, Ray SD, Sen CK, Preuss HG. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci 2002;957:260-70.
7. Bartolome B, Hernandez T, Bengoechea ML, Quesada C, Gomez-Cordoves C, Estrella I. Determination of some structural features of procyanidins and related compounds by photodiode-array detection. J Chromatogr A 1996;723:19-26.
8. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-69.
9. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila) 2009;2:514-7.
10. Bomser JA, Singletary KW, Wallig MA, Smith MA. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds. Cancer Lett 1999;135:151-7.
11. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res 2008;58:8-14.
12. Borrelli F, Izzo AA. Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009;11:710-27.
13. Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy. A quick reference to herbal medicine. Berlin: Springer-Verlag, 2003.
14. Chan K, Lo AC, Yeung JH, Woo KS. The effects of danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol 1995;47:402-6.
15. Chan TY: Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 2001;35: 501-4.
16. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67:3103-12.
17. Choi YH, Chin YW, Kim YG. Herb-drug interactions: focus on metabolic enzymes and transporters. Arch Pharm Res 2011;34:1843-63.
18. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006;15:2473-6.
19. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA et al. Resveratrol modulates drug-and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 2010;3:1168-75.
20. Circosta C, De Pasquale RD, Palumbo DR, Samperi S, Occhiuto F. Estrogenic activity of standardized extract of Angelica sinensis. Phytother Res 2006;20: 665-9.
21. Cui Y, Yan ZH, Hou SL, Chang ZF. Effect of Shudihuang on the transmitter and receptor of amino acid in brain and learning and memory of dementia model. China J Chin Mater Med (chin) 2003;28:862-6.
22. Deka A, Vita JA. Tea and cardiovascular disease. Pharmacol Res 2011;64:136-45.
23. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleuthe-roccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003;31: 519-22.
24. Donovan JL, Chavin KD, Devane CL, Taylor RM, Wang JS, Ruan Y et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32:906-8. Erratum in: Drug Metab Dispos 2004;32:1331.
25. Draves AH, Walker SE. Analysis of the hypericin and pseudohypericin content of commercially available St. John’s wort preparations. Can J Clin Pharmacol 2003;10:114-8.
26. Dreosti IE, Wargovich MJ, Yang CS. Inhibition of carcinogenesis by tea: the evidence from experimental studies. Crit Rev Food Sci Nutr 1997;37:761-70.
27. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M et al. Trends in alternative medicine use in the united states, 1990-1997-results of a follow-up national survey. JAMA 1998;280: 1569-75.
28. Ellis GR, Stephens MR. Untitled (photograph and brief case report). BMJ 1999;19:650.
29. Ernst E, Pittler MH, Wider B, Boddy K. Oxford handbook of complementary medicine. Oxford: Oxford Univ. Press, 2008.
30. Fasinu P, Bouic P, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol 2012;3:1-19.
31. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10:334-42.
32. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer Ch, Birkhäuser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005;51:397-404.
33. Fu RZ, Wang J, Zhang YB, Wang ZT, But PP, Li N et al. Differentiation of medicinal Codonopsis species from adulterants by polymerase chain reactionrestriction fragment length polymorphism. Planta Med 1999;65:648-50.
34. Fugh Berman A. Herb-drug interactions. Lancet 2000;355:134-8.
35. Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evid Based Complement Alternat Med 2014;2014:957362.
36. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156-66.
37. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21.
38. Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 2013;39: 773-83.
39. Greenblatt DJ, von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005;45:127-32.
40. Guerra MC, Speroni E, Broccoli M, Cangini M, Pasini P, Minghett A et al. Comparison between chinese medical herb Pueraria lobata crude extract and its main isoflavone puerarin antioxidant properties and effects on rat liver CYP-catalysed drug metabolism. Life Sci 2000;67:2997-3006.
41. Gupta S, Zhang D, Yi J, Shao J. Anticancer activities of Oldenlandia diffusa. J Herb Pharmacother 2004;4: 21-33.
42. Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 2000;57:963-9.
43. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87.
44. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76: 428-40.
45. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77:415-26.
46. Gurley BJ, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006;46:201-13.
47. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008a;83:61-9.
48. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008b;52:755-63.
49. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med 2012;78:1490-514.
50. Halpern MJ, Dahlgren AL, Laasko I, Seppanen-Laasko T, Dahlgren J, McAnulty PA. Red-wine polyphenols and inhibition of platelet aggregation: possible mechanisms, and potential use in health promotion and disease prevention. J Int Med Res 1998;26: 171-80.
51. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001;73:1101-6.
52. Hatfield MJ, Tsurkan LG, Hyatt JL, Edwards CC, Lemoff A, Jeffries C et al. Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen"). J Nat Prod 2013;76:36-44.
53. Hayat K, Iqbal H, Malik U, Bilal U, Mushtaq S. Tea and its consumption: benefits and risks. Crit Rev Food Sci Nutr 2013; Sep 20. [Epub ahead of print].
54. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7.
55. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999;65:PL209-14.
56. Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78:1458-77.
57. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertility Steril 1997;68:981-6.
58. Ho SH, Singh M, Holloway AC, Crankshaw DJ. The effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450. Phytother Res 2011;25:983-9.
59. Hu Z, Yang, X, Ho PCL, Chan SY, Heng PWS, Chan E et al. Herb-drug interactions, a literature review. Drugs 2005;65:1239-82.
60. Huang Y, Jiang B, Nuntanakorn P, Kennelly EJ, Shord S, Lawal TO et al. Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro. Curr Drug Saf 2010;5:118-24.
61. Izzo A. Herb-drug interactions: an overview of the clinical evidence. Fund Clin Pharmacol 2005;19:1-16.
62. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract 2012;21:404-28.
63. Izzo A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69:1777-98.
64. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9.
65. Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokineticpharmacodynamic modeling approach. J Clin Pharmacol 2006;46:1370-8.
66. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
67. Johne A, Roots I. Clinical drug interactions with medicinal herbs. Evid Based Integr Med 2005;2:207-28.
68. Juangsu New Medical College, “Zhong Yao Da Ci Dian” (Dictionary of Chinese Materia Medica, Vol. II, pp 1837-9). Shanghai: Shanghai Scientific and Technological Publisher, 1979.
69. Kan WL, Cho CH, Rudd JA, Lin G. Study of the antiproliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells. J Ethnopharmacol 2008;120:36-43.
70. Katiyar S, Mukhtar H. Tea in chemoprevention of cancer. Int J Oncol 1996;8:221-38.
71. Kaur M, Agarwal C, Agarwal R. Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr 2009;139: 1806S-12S.
72. Khokhar S, Magnusdottir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J Agric Food Chem 2002;50:565-70.
73. Kim H, Lee E, Lee S, Shin T, Kim Y, Kim J. Effect of Rehmannia glutinosa on immediate type allergic reaction. Int J Immunopharmacol 1998;20:231-40.
74. Kim HM, An CS, Jung KY, Choo YK, Park JK, Nam SY. Rehmannia glutinosa inhibits tumour necrosis factor-alpha and interleukin-1 secretion from mouse astrocytes. Pharmacol Res 1999;40:171-6.
75. Kuo YH, Lin YL, Don MJ, Chen RM, Ueng YF. Induction of cytochrome P450 dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J Pharm Pharmacol 2006;58:521-6.
76. Lambert JD, Sang S, Lu AY, Yang CS. Metabolism of dietary polyphenols and possible interactions with drugs. Curr Drug Metab 2007;8:499-507.
77. Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JHM, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol 2013;149:543-9.
78. Lebot V, Merlin M, Lindstrom L. Kava-the pacific elixir: the definitive guide to its ethnobotany, history, and chemistry. New Haven, CT: Yale Univ. Press, 1997.
79. Leung AY. Traditional toxicity documentation of Chinese Materia Medica: an overview. Toxicol Pathol 2006;34:319-26.
80. Li JX, Yu ZY. Cimicifugae rhizoma: from origins, bioactive constituents to clinical outcomes. Curr Med Chem 2006;13:2927-51.
81. Li J, Gödecke T, Chen SN, Imai A, Lankin DC, Farnsworth NR et al. In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. Xenobiotica 2011;41:1021-30.
82. Lim ST, Dragull K, Tang CS, Bittenbender HC, Efird JT, Nerurkar PV. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci 2007;97: 214-21.
83. Liske E, Hänggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P, Rahlfs VW. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11:163-74.
84. Maffei FR, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E et al. Procyanidins from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 1996;62:495-502.
85. Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri-and postmenopausal women. Menopause 2003;10:65-72.
86. Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (Pgp) activity in healthy participants. J Clin Pharmacol 2012;52:932-9.
87. Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003;74:536-42.
88. McKenna DJ, Jones K, Humphrey S, Hughes K. Black cohosh: efficacy, safety, and use in clinical and preclinical applications. Altern Ther Health Med 2001;7:93-100.
89. Moore RJ, Jackson KG, Minihane AM. Green tea (Camellia sinensis) catechins and vascular function. Br J Nutr 2009;102:1790-802.
90. Niemi, M, Backman J, Fromm M, Neuvonen P, Kivist K. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-50.
91. Nuntanakorn P, Jiang B, Einbond LS, Yang H, Kronenberg F, Weinstein IB et al. Polyphenolic constituents of Actaea racemosa. J Nat Prod 2006;69:314-8.
92. Ovesna Z, Vachalkova A, Horvathova K, Tothova D. Pentacyclic triterpenoic acids: New chemoprotective compounds. Neoplasma 2004;51:327-33.
93. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999;319:870-6.
94. Pal D, Mitra A. MDR-and CYP3A4-mediated drugherbal interactions. Life Sci 2006;78:2131-45.
95. Pang X, Cheng J, Krausz KW, Guo D, Gonzalez FJ. Pregnane X receptor-mediated induction of CYP3A by black cohosh. Xenobiotica 2011;41:112-23.
96. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004;11:262-77.
97. Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey RT Jr. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol 2008;48:671-80.
98. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91.
99. Qi L-W, Wang C-Z, Du G-J, Zhang Z-Y, Calway T, Yuan C-S. Metabolism of ginseng and its interactions with drugs. Curr Drug Metab 2011;12:818-22.
100. Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y et al. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 2008;36:1308-14.
101. Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y. Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol 2010;69:656-62.
102. Renaud S, De Lorgeril M. Wine, alcohol, platelets and the French Paradox for coronary heart disease. Lancet 1992;339:1523-6.
103. Rodríguez-Fragoso L, Martínez-Arismendi JL, Orozco-Bustos D, Reyes-Esparza J, Torres E, Burchiel SW. Potential risks resulting from fruit/vegetabledrug interactions: effects on drug-metabolizing enzymes and drug transporters. J Food Sci 2011;76: R112-24.
104. Russmann S, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K et al. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: Protective effect against environmental carcinogens? Clin Pharmacol Ther 2005;77:453-4.
105. Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry 2011;45:27-3.
106. Schönthal AH. Adverse effects of concentrated green tea extracts. Mol Nutr Food Res 2011;55:874-85.
107. Scripture C, Figg W. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546-58.
108. Sevior DK, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O et al. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010;40:245-54.
109. Sharma G, Tyagi AK, Singh RP, Chan DC, Agarwal R. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat 2004;85:1-12.
110. Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012;51:77-104.
111. Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 2009;8:208-27.
112. Singleton VL. Tannins and the qualities of wines. In: Laks PE, Hemingway RW (eds): Plant polyphenols (pp 859-80). New York: Plenum Press, 1992.
113. Soleas GJ, Diamandis EP, Goldberg DM. Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 1997;11:287-313.
114. Song X, Siriwardhana N, Rathore K, Lin D, Wang HC. Grape seed proanthocyanidin suppression of breast cell carcinogenesis induced by chronic exposure to combined 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Mol Carcinog 2010;49:450-63.
115. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: Potential adverse reactions with anticancer drugs. J Clin Oncol 2004;22:2489-503.
116. Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000;59:420-2.
117. Sturgeon JL, Williams M, van Servellen G. Efficacy of green tea in the prevention of cancers. Nurs Health Sci 2009;11:436-46.
118. Sui Y, Zhao HL, Wong VCW, Brown N, Li XL, Kwan AKL et al. A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes Rev 2012;13:409-30.
119. Sung Y-Y, Yoon T, Jang JY, Park S-J, Kim HK. Topical application of Rehmannia glutinosa extract inhibits mite allergen-induced atopic dermatitis in NC/Nga mice. J Ethnopharmacol 2011;134:37-44.
120. Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;3:CD001423. doi:10.1002/14651858.
121. Tang JC, Zhang JN, Wu YT, Li ZX. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res 2006;20:1046-51.
122. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999;33:426-8.
123. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30: 1270-9.
124. Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. JAMA2010;304:2174-5.
125. Tsai HH, Lin HW, Lu YH, Chen YL, Mahady GB. A review of potential harmful interactions between anticoagulant/ antiplatelet agents and Chinese herbal medicines. PloS One 2013;8:e64255.
126. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). eCAM 2005;2:223-6.
127. US Department of Health and Human Services/Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations (February 2012). Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM292362.pdf Accessed February 11, 2013.
128. van Breeman RB, Liang W, Banuvar S, Shulman LP, Pang Y, Tao Y et al. Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh. Clin Pharmacol Ther 2010;87:219-25.
129. Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen?. Trend Endocrinol Metab 2005;16:214-21.
130. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
131. Wang J, Zou W. Practices, challenges, and opportunities: HIV/AIDS treatment with traditional Chinese medicine in China. Front Med 2011;5:123-6.
132. Wanwimolruk S, Prachayasittikul V. Variable inhibitory effect of herbal supplements of different brands on human P450 CYP1A2. EXCLI J 2012;11:7-19.
133. Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J 2014;13:347-91.
134. Wanwimolruk S, Wong K, Wanwimolruk P. Variable inhibitory effect of commercial herbal supplements with different brands on human cytochrome P-450 CYP3A4. Drug Metabol Drug Interact 2009;24:17-35.
135. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
136. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-13.
137. Wong R, Sagar CM, Sagar SM. Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 2001; 27:235-46.
138. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE et al. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993;25:453-84.
139. Wrighton SA, Thummel KE. CYP3A. In: Levy H, Thummel K, Trager W, Hansten P, Eichelbaum M (eds): Metabolic drug interactions (pp 115-34). New York: Lippincott Williams & Wilkins, 2000.
140. Wu P-S, Wu S-J, Tsai Y-H, Lin Y-H, Chao JC-J. Hot water extracted Lycium barbarum and Rehmannia glutinosa inhibit liver inflammation and fibrosis in rats. Am J Chinese Med 2011;39:1173-91.
141. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44(Suppl 1):S67-S77.
142. Xu W, Towers AD, Li P, Collet J. Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China. Eur J Cancer Care 2006;15:397-403.
143. Yang CS, Pan E. The effects of green tea polyphenols on drug metabolism. Expert Opin Drug Metab Toxicol 2012;8:677-89.
144. Yang CS, Wang H. Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res 2011;55:819-31.
145. Yang CS, Lee MJ, Chen L, Yang GY. Polyphenols as inhibitors of carcinogenesis. Environ Health Perspect 1997;105(Suppl 4):971-6.
146. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42:25-54.
147. Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H. Cancer prevention by tea: Evidence from laboratory studies. Pharmacol Res 2011;64:113-22.
148. Ye X, Krohn RL, Liu W, Joshi SS, Kuszynski CA, McGinn TR et al. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol Cell Biochem 1999; 196:99-108.
149. Yoo HH, Kim SA, Kim IS, Ko SG. The evaluation of CP-001 (a standardized herbal mixture of Houttuynia cordata, Rehmannia glutinosa, Betula platyphylla, and Rubus coreanus) for cytochrome P450-related herbdrug interactions. Evid Based Complement Alternat Med 2013;2013:824.
150. Youns M, Hoheisel J, Efferth T. Toxicogenomics for the prediction of toxicity related to herbs from traditional Chinese medicine. Planta Med 2010;76: 2019-25.
151. Yu CM, Chan JC, Sanderson JE: Chinese herbs and warfarin potentiation by danshen. J Intern Med 1997; 25:337-9.
152. Yu C, Ye S, Sun H, Liu Y, Gao L, Shen C et al. PXRmediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA. Chem Biol Interact 2009;177:58-64.
153. Yu C, Chai X, Yu L, Chen S, Zeng S. Identification of novel pregnane X receptor activators from traditional Chinese medicines. J Ethnopharmacol 2011; 136:137-43.
154. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S et al. American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004;141:23-7.
155. Zadoyan G, Fuhr U. Phenotyping studies to assess the effects of phytopharmaceuticals on in vivo activity of main human cytochrome P450 enzymes. Planta Med 2012;78:1428-57.
156. Zanger U, Eichelbaum M. CYP2D6. In: Levy H, Thummel K, Trager W, Hansten P, Eichelbaum M (eds): Metabolic drug interactions (pp 87-94). New York: Lippincott Williams & Wilkins, 2000.
157. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. Evidence for an involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 1997;43:245-52.
158. Zhang P, Li J, Han Y, Yu X, Qin L. Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review. Rheum Intern 2010;30:713-8.
159. Zhang R, Li M, Jia Z. Rehmannia glutinosa: review of botany, chemistry and pharmacology. J Ethnopharmacol 2008;117:199-214.
160. Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumorpromoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidins B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis 1999;20:1737-45.
161. Zheng T, Boyle P, Willett WC, Hu H, Dan J, Evstifeeva TV et al. A case-control study of oral cancer in Beijing, People’s Republic of China. Associations with nutrient intakes, foods and food groups. Eur J Cancer Biol Oral Oncol 1993;29B:45-55.
162. Zhou X, Chan K, Yeung JH. Herb-drug interactions with Danshen (Salvia miltiorrhiza): a review on the role of cytochrome P450 enzymes. Drug Metabol Drug Interact 2012;27:9-18.